U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07059494) titled 'Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant' on June 17.
Brief Summary: A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP >= 400 ng/ml as a means of bridge therapy prior to transplant, 2) beyond the Milan Criteria (MC) (within USCF DS criteria and all comers), as a means of downstaging prior to liver transplantation.
Study Start Date: Aug., 2025
Study Type: INTERV...